Trial Profile
A Pilot Study To Evaluate The Safety And Feasibility of Hematopoietic Progenitor Cell Mobilization With Plerixafor as Part of a Gene Therapy Strategy in Sickle Cell Disease
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 26 Feb 2024
Price :
$35
*
At a glance
- Drugs Plerixafor (Primary)
- Indications Sickle cell anaemia
- Focus Adverse reactions
- Acronyms PISMO
- 20 Feb 2024 Planned End Date changed from 31 Dec 2023 to 6 Sep 2024.
- 20 Feb 2024 Planned primary completion date changed from 31 Dec 2023 to 6 Sep 2024.
- 19 Feb 2023 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.